scholarly journals Oligonucleotide-templated lateral flow assays for amplification-free sensing of circulating microRNAs

2019 ◽  
Vol 55 (83) ◽  
pp. 12451-12454 ◽  
Author(s):  
Suraj Pavagada ◽  
Robert B. Channon ◽  
Jason Y. H. Chang ◽  
Sung Hye Kim ◽  
David MacIntyre ◽  
...  
Keyword(s):  
Preterm Birth ◽  
Minimally Invasive ◽  
Low Cost ◽  
Maternal Blood ◽  
Lateral Flow ◽  
Early Prediction ◽  
Circulating Micrornas ◽  
Lateral Flow Assays

Low-cost detection of miRNA biomarkers from maternal blood is achieved via a highly sequence-specific templated reaction on nitrocellulose paper strips to enable early prediction of preterm birth in a minimally invasive manner.

scholarly journals Integrating high-performing electrochemical transducers in lateral flow assay

2021 ◽  
Author(s):  
Antonia Perju ◽  
Nongnoot Wongkaew
Keyword(s):  
High Performance ◽  
Point Of Care ◽  
Low Cost ◽  
High Sensitivity ◽  
Lateral Flow ◽  
Analytical Performance ◽  
Label Free ◽  
High Performing ◽  
Lateral Flow Assays ◽  
Electrochemical Transducers

AbstractLateral flow assays (LFAs) are the best-performing and best-known point-of-care tests worldwide. Over the last decade, they have experienced an increasing interest by researchers towards improving their analytical performance while maintaining their robust assay platform. Commercially, visual and optical detection strategies dominate, but it is especially the research on integrating electrochemical (EC) approaches that may have a chance to significantly improve an LFA’s performance that is needed in order to detect analytes reliably at lower concentrations than currently possible. In fact, EC-LFAs offer advantages in terms of quantitative determination, low-cost, high sensitivity, and even simple, label-free strategies. Here, the various configurations of EC-LFAs published are summarized and critically evaluated. In short, most of them rely on applying conventional transducers, e.g., screen-printed electrode, to ensure reliability of the assay, and additional advances are afforded by the beneficial features of nanomaterials. It is predicted that these will be further implemented in EC-LFAs as high-performance transducers. Considering the low cost of point-of-care devices, it becomes even more important to also identify strategies that efficiently integrate nanomaterials into EC-LFAs in a high-throughput manner while maintaining their favorable analytical performance.

scholarly journals Electrospun Polycaprolactone Nanofibers as a Reaction Membrane for Lateral Flow Assay

Polymers ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1387 ◽  
Author(s):  
Chee Yew ◽  
Pedram Azari ◽  
Jane Choi ◽  
Farina Muhamad ◽  
Belinda Pingguan-Murphy
Keyword(s):  
Flow Rate ◽  
Point Of Care ◽  
Low Cost ◽  
Average Pore Size ◽  
Lateral Flow ◽  
Detection Sensitivity ◽  
Average Pore ◽  
Water Contact ◽  
Naoh Solution ◽  
Lateral Flow Assays

Electrospun polycaprolactone (PCL) nanofibers have emerged as a promising material in diverse biomedical applications due to their various favorable features. However, their application in the field of biosensors such as point-of-care lateral flow assays (LFA) has not been investigated. The present study demonstrates the use of electrospun PCL nanofibers as a reaction membrane for LFA. Electrospun PCL nanofibers were treated with NaOH solution for different concentrations and durations to achieve a desirable flow rate and optimum detection sensitivity in nucleic acid-based LFA. It was observed that the concentration of NaOH does not affect the physical properties of nanofibers, including average fiber diameter, average pore size and porosity. However, interestingly, a significant reduction of the water contact angle was observed due to the generation of hydroxyl and carboxyl groups on the nanofibers, which increased their hydrophilicity. The optimally treated nanofibers were able to detect synthetic Zika viral DNA (as a model analyte) sensitively with a detection limit of 0.5 nM. Collectively, the benefits such as low-cost of fabrication, ease of modification, porous nanofibrous structures and tunability of flow rate make PCL nanofibers a versatile alternative to nitrocellulose membrane in LFA applications. This material offers tremendous potential for a broad range of point-of-care applications.

scholarly journals Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection

2020 ◽  
Author(s):  
Susanna K. Elledge ◽  
Xin X. Zhou ◽  
James R. Byrnes ◽  
Alexander J. Martinko ◽  
Irene Lui ◽  
...  
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Low Cost ◽  
Lateral Flow ◽  
Antibody Detection ◽  
Lateral Flow Assays ◽  
Quantitative Results ◽  
Development And Validation ◽  
Antibody Tests ◽  
Split Luciferase

Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with the former being laborious and the latter being expensive and often lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost solution-based assay to detect antibodies in serum, plasma, whole blood, and saliva, using rationally designed split luciferase antibody biosensors (spLUC). This new assay, which generates quantitative results in as short as 5 minutes, substantially reduces the complexity and improves the scalability of COVID-19 antibody tests for point-of-care and broad population testing.

Improving Lateral Flow Assay Performance Using Computational Modeling

2018 ◽  
Vol 11 (1) ◽  
pp. 219-244 ◽  
Author(s):  
David Gasperino ◽  
Ted Baughman ◽  
Helen V. Hsieh ◽  
David Bell ◽  
Bernhard H. Weigl
Keyword(s):  
Computational Models ◽  
Low Cost ◽  
Diagnostic Testing ◽  
Computational Design ◽  
Lateral Flow ◽  
Health Care Practices ◽  
Assay Performance ◽  
Lateral Flow Assays ◽  
Global Health Care ◽  
Underlying Processes

The performance, field utility, and low cost of lateral flow assays (LFAs) have driven a tremendous shift in global health care practices by enabling diagnostic testing in previously unserved settings. This success has motivated the continued improvement of LFAs through increasingly sophisticated materials and reagents. However, our mechanistic understanding of the underlying processes that drive the informed design of these systems has not received commensurate attention. Here, we review the principles underpinning LFAs and the historical evolution of theory to predict their performance. As this theory is integrated into computational models and becomes testable, the criteria for quantifying performance and validating predictive power are critical. The integration of computational design with LFA development offers a promising and coherent framework to choose from an increasing number of novel materials, techniques, and reagents to deliver the low-cost, high-fidelity assays of the future.

scholarly journals Lateral flow assays

2016 ◽  
Vol 60 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Katarzyna M. Koczula ◽  
Andrea Gallotta
Keyword(s):  
Low Cost ◽  
Lateral Flow ◽  
Environmental Sciences ◽  
Advantages And Disadvantages ◽  
Recent Advances ◽  
Portable Detection ◽  
Lateral Flow Assays ◽  
Critical Components ◽  
Diagnostic Applications ◽  
Interpretation Of Results

Lateral flow assays (LFAs) are the technology behind low-cost, simple, rapid and portable detection devices popular in biomedicine, agriculture, food and environmental sciences. This review presents an overview of the principle of the method and the critical components of the assay, focusing on lateral flow immunoassays. This type of assay has recently attracted considerable interest because of its potential to provide instantaneous diagnosis directly to patients. The range and interpretation of results and parameters used for evaluation of the assay will also be discussed. The main advantages and disadvantages of LFAs will be summarized and relevant future improvements to testing devices and strategies will be proposed. Finally, the major recent advances and future diagnostic applications in the LFA field will be explored.

scholarly journals Correction: Oligonucleotide-templated lateral flow assays for amplification-free sensing of circulating microRNAs

2019 ◽  
Vol 55 (89) ◽  
pp. 13470-13470
Author(s):  
Suraj Pavagada ◽  
Robert B. Channon ◽  
Jason Y. H. Chang ◽  
Sung Hye Kim ◽  
David MacIntyre ◽  
...  
Keyword(s):  
Lateral Flow ◽  
Circulating Micrornas ◽  
Lateral Flow Assays

Correction for ‘Oligonucleotide-templated lateral flow assays for amplification-free sensing of circulating microRNAs’ by Suraj Pavagada et al., Chem. Commun., 2019, 55, 12451–12454.

scholarly journals A Low-Cost, High-Performance System for Fluorescence Lateral Flow Assays

Biosensors ◽  
2013 ◽  
Vol 3 (4) ◽  
pp. 360-373 ◽  
Author(s):  
Linda Lee ◽  
Eric Nordman ◽  
Martin Johnson ◽  
Mark Oldham
Keyword(s):  
High Performance ◽  
Low Cost ◽  
Lateral Flow ◽  
Lateral Flow Assays ◽  
Performance System

scholarly journals Integrated Nanomaterials and Nanotechnologies in Lateral Flow Tests for Personalized Medicine Applications

Nanomaterials ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 2362
Author(s):  
Lucia Napione
Keyword(s):  
Personalized Medicine ◽  
Patient Monitoring ◽  
Low Cost ◽  
Detection Threshold ◽  
Accurate Method ◽  
Lateral Flow ◽  
Diagnostic Tools ◽  
Lateral Flow Assays ◽  
The Right ◽  
Lateral Flow Tests

The goal of personalized medicine is to target the right treatments to the right patients at the right time. Patients with a variety of cancers and other complex diseases are regularly tested as part of patient care, enabling physicians to personalize patient monitoring and treatment. Among the sought-after diagnostic tools, there is an increasing interest and need for those based on a low-cost, easy, rapid, and accurate method for the detection of specific circulating biomarkers above a detection threshold. Lateral flow tests (LFTs), enhanced by nanotechnology, can fulfil these requirements, providing a significant support to personalized patient monitoring. In this review, after a short historical synopsis of membrane-based lateral flow assays, including a description of a typical configuration of a LFT strip, a careful collection is presented of the best characterized nanotechnology approaches previously reported for the enhancement of target detection performance. The attempt is to offer an overview of currently integrated nanotechnologies in LFTs, fostering the actual future development of advantageous diagnostic devices for patient monitoring.

A two-dimensional mathematical model for analyzing the effects of capture probe properties on the performance of lateral flow assays

The Analyst ◽  
2019 ◽  
Vol 144 (18) ◽  
pp. 5394-5403
Author(s):  
Zhi Liu ◽  
Xiaocong He ◽  
Ang Li ◽  
Zhiguo Qu ◽  
Feng Xu
Keyword(s):  
Mathematical Model ◽  
Low Cost ◽  
Lateral Flow ◽  
Capture Probe ◽  
Two Dimensional ◽  
Biomedical Diagnosis ◽  
Lateral Flow Assays

Lateral flow assays (LFAs) are promising candidates in biomedical diagnosis fields due to their rapid, low-cost, and portable features.

scholarly journals Evaluation of rapid, cassette immunochromatographic tests in the serological diagnosis of COVID-19

2021 ◽  
pp. 25-37
Author(s):  
Waldemar Rastawicki ◽  
Klaudia Płaza ◽  
Adam Pietrusiński
Keyword(s):  
Low Cost ◽  
Lateral Flow ◽  
Serological Diagnosis ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Serological Tests ◽  
Negative Results ◽  
Lateral Flow Assays ◽  
Low Sensitivity ◽  
Positive Results

Introduction: Lateral flow assays (LFIA) are the technology behind low-cost, simple, rapid and portable detection devices popular in biomedicine. Lately, they are very common used in serodiagnosis of SARS-CoV-2 infections. The aim of the presented study was to assess the usefulness of selected LFIA in serological diagnosis of COVID-19. Methods: The usefulness of seven lateral flow assays in the serodiagnosis of COVID-19 was evaluated (VAZYME, DIAGNOSIS, PCL, INGEZIM, BIOSENSOR, ACCU-TELL, NOVAtest). The study used 107 serum samples obtained from 74 individuals with current SARS-CoV-2 infection confirmed by RT-PCR. The ELISA-IgG (Euroimmun) was used as the reference assay for sensitivity and specificity testing. Results: The highest percentage of positive results was obtained when searching for IgG antibodies with the NOVAtest (40.6%) and DIAGNOSIS (39.2%) sets and the lowest detection for the PCL set - 25.5%. In the case of searching for IgM antibodies in all sets, significantly lower percentages of positive results compared to the IgG class were recorded. In general, all lateral flow assays showed low sensitivity in relation to the Euroimmun ELISA-IgG. The DIAGNOSIS kit (64.5%) was characterized by the highest sensitivity, and the PCL kit was the lowest (38.7%). On the other hand, the specificity of all kits was very high, almost 100% in almost all cases. Conclusions: Lateral flow assays due to their low sensitivity are not suitable for quick diagnosis of the current SARS-CoV-2 infections and cannot be an alternative to genetic or even antigen tests. They may be used only to retrospectively test the presence of IgG antibodies. However, a negative results of LFIA in suspected disease or after vaccination should be confirmed by more sensitive serological tests.

Sign in / Sign up

Export Citation Format

Share Document